Ozer H, Wiernik P H, Giles F, Tendler C
Allegheny University Cancer Center, Allegheny University of the Health Sciences, Philadelphia, Pennsylvania 19102, USA.
Cancer. 1998 May 15;82(10):1821-30.
Advanced stage, follicular, non-Hodgkin's lymphoma (NHL) has no cure and no single standard of care. Remissions induced by standard chemotherapy regimens generally are not durable and, with the exception of selected patients with limited early stage disease, most patients with follicular NHL eventually die of their disease. Recombinant interferon-alpha (rIFN-alpha) has demonstrated activity against follicular NHL in clinical trials.
A comprehensive survey of current therapeutic options for follicular NHL patients was conducted with emphasis on the role of rIFN-alpha used in conjunction with chemotherapy regimens.
Phase III studies have demonstrated that rIFN-alpha delays disease progression and may improve overall survival when administered either with chemotherapy or as maintenance therapy after induction treatment for follicular lymphoma. Adverse effects from combination or maintenance regimens are not significantly different from those from chemotherapy alone.
Recombinant IFN-alpha is safe and effective when given in conjunction with standard chemotherapeutic regimens in selected patients with follicular NHL, and may especially benefit patients with minimal residual disease after induction chemotherapy.
晚期滤泡性非霍奇金淋巴瘤（NHL）无法治愈，也没有单一的标准治疗方案。标准化疗方案诱导的缓解通常不持久，除了少数早期疾病局限的患者外，大多数滤泡性NHL患者最终死于该疾病。重组干扰素-α（rIFN-α）在临床试验中已显示出对滤泡性NHL的活性。
对滤泡性NHL患者当前的治疗选择进行了全面调查，重点是rIFN-α与化疗方案联合使用的作用。
III期研究表明，rIFN-α与化疗联合使用或在滤泡性淋巴瘤诱导治疗后作为维持治疗时，可延迟疾病进展并可能改善总生存期。联合或维持方案的不良反应与单纯化疗的不良反应无显著差异。
在选定的滤泡性NHL患者中，重组IFN-α与标准化疗方案联合使用时是安全有效的，对诱导化疗后残留疾病最少的患者可能尤其有益。
